Tumor targeting via integrin ligands

Frontiers in Oncology

Volumn 3 AUG, Issue , 2013, Pages

  Marelli, Udaya Kiran ^a   Rechenmacher, Florian ^a   Ali Sobahi, Tariq Rashad ^b   Mas Moruno, Carlos ^c   Kessler, Horst ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

Author keywords

v 3; v 5; A5 1 and v 6; Integrins; RGD; Targeted delivery; Tumor

Indexed keywords

ADENOVIRUS VECTOR; ALBENDAZOLE; ALPHAVBETA5 INTEGRIN; ALPHAVBETA6 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; CILENGITIDE; COLLAGEN; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; FIBRONECTIN; FLUOROURACIL; FUMAGILLIN; GELDANAMYCIN; GEMCITABINE; GRAPHENE OXIDE; INTEGRIN; NANOSPHERE; PACLITAXEL; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN; VITRONECTIN RECEPTOR;

ALLERGIC REACTION; ANGIOGENESIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER THERAPY; CARDIOTOXICITY; DRUG SOLUBILITY; DRUG TARGETING; GENE THERAPY; HUMAN; MOLECULARLY TARGETED THERAPY; NEUROTOXICITY; NONHUMAN; PHOTOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; VIRUS LIKE AGENT;

EID: 84887137018     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00222     Document Type: Article

References (121)

1. Kumar S, Mahdi H, Bryant C, Shah JP, Garg G, Munkarah A. Clinical trials and progress with paclitaxel in ovarian cancer. Int J Womens Health (2010) 2:411-27. doi:10.2147/IJWH.S7012
2. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol (1990) 8:1263-8.
3. Prados J, Melguizo C, Ortiz R, Vélez C, Alvarez PJ, Arias JL, et al. Doxorubicin-loaded nanoparticles: new advances in breast cancer therapy. Anticancer Agents Med Chem (2012) 12:1058-70. doi:10.2174/187152012803529646
4. Lao J, Madani J, Puértolas T, Álvarez M, Hernández A, Pazo-Cid R, et al. Liposomal doxorubicin in the treatment of breast cancer patients: a review. J Drug Deliv (2013) 456409:1-12. doi:10.1155/2013/456409
5. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat (2002) 5:19-33. doi:10.1016/S1368-7646(02)00002-X
6. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets (2003) 3:1-19. doi:10.2174/1568009033333754
7. Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem (2007) 2:920-42. doi:10.1002/cmdc.200600308
8. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2010) 10:9-22. doi:10.1038/nrc2748
9. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer (2002) 2:83-90. doi:10.1038/nrc724
10. Teesalu T, Sugahara KN, Ruoslahti E. Mapping of vascular ZIP codes by phage display. Methods Enzymol (2012) 503:35-56. doi:10.1016/B978-0-12-396962-0.00002-1
11. Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci (2012) 33:405-12. doi:10.1016/j.tips.2012.04.002
12. Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res (2010) 339:269-80. doi:10.1007/s00441-009-0834-6
13. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature (1984) 309:30-3. doi:10.1038/309030a0
14. Cabodi S, Di Stefano P, Leal Mdel P, Tinnirello A, Bisaro B, Morello V, et al. Integrins and signal transduction. Adv Exp Med Biol (2010) 674:43-54. doi:10.1007/978-1-4419-6066-5_5
15. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov (2010) 9:804-20. doi:10.1038/nrd3266
16. Weis SM, Cheresh DA. aV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med (2011) 1:a006478. doi:10.1101/cshperspect.a006478
17. Rathinam R, Alahari SK. Important role of integrins in the cancer biology. Cancer Metastasis Rev (2010) 29:223-37. doi:10.1007/s10555-010-9211-x
18. Moschos SJ, Drogowski LM, Reppert SL, Kirkwood JM. Integrins and cancer. Oncology (Williston Park, N Y) (2007) 21:13-20.
19. Temming K, Schiffelers RM, Molema G, Kok RJ. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat (2005) 8:381-402. doi:10.1016/j.drup.2005.10.002
20. Park J, Singha K, Son S, Kim J, Namgung R, Yun CO, et al. A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy. Cancer Gene Ther (2012) 19:741-8. doi:10.1038/cgt.2012.64
21. Danhier F, Le Breton A, Préat V. RGD-based strategies to target avß3 integrin in cancer therapy and diagnosis. Mol Pharm (2012) 9:2961-73. doi:10.1021/mp3002733
22. Chen K, Chen X. Integrin targeted delivery of chemotherapeutics. Theranostics (2011) 1:189-200. doi:10.7150/thno/v01p0189
23. Ruoslahti E. The RGD story: a personal account. Matrix Biol (2003) 22:459-65. doi:10.1016/S0945-053X(03)00083-0
24. Meyer A, Auernheimer J, Modlinger A, Kessler H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des (2006) 12:2723-47. doi:10.2174/138161206777947740
25. Aumailley M, Gurrath M, Müller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett (1991) 291:50-4. doi:10.1016/0014-5793(91)81101-D
26. Chatterjee J, Gilon C, Hoffman A, Kessler H. N-methylation of peptides: a new perspective in medicinal chemistry. Acc Chem Res (2008) 41:1331-42. doi:10.1021/ar8000603
27. Chatterjee J, Rechenmacher F, Kessler H. N-methylation of peptides and proteins: an important element for modulating biological functions. Angew Chem Int Ed Engl (2013) 52:254-69. doi:10.1002/anie.201205674
28. Dechantsreiter MA, Planker E, Mathä B, Lohof E, Hölzemann G, Jonczyk A, et al. N-methylated cyclic RGD peptides as highly active and selective avß3 integrin antagonists. J Med Chem (1999) 42:3033-40. doi:10.1021/jm970832g
29. Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem (2010) 10:753-68. doi:10.2174/187152010794728639
30. Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin avß3 antagonists. J Am Chem Soc (1996) 118:7461-72. doi:10.1021/ja9603721
31. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Nat Biotechnol (1995) 13:265-70. doi:10.1038/nbt0395-265
32. Hajitou A. Targeted systemic gene therapy and molecular imaging of cancer contribution of the vascular-targeted AAVP vector. Adv Genet (2010) 69:65-82. doi:10.1016/S0065-2660(10)69008-6
33. Smaglik P. Merck blocks "safer" gene therapy trials. Nature (2000) 403:817. doi:10.1038/35002743
34. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007-an update. J Gene Med (2007) 9:833-42. doi:10.1002/jgm.1100
35. Hovlid ML, Steinmetz NF, Laufer B, Lau JL, Kuzelka J, Wang Q, et al. Guiding plant virus particles to integrin-displaying cells. Nanoscale (2012) 4:3698-705. doi:10.1039/c2nr30571b
36. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer (2008) 8:604-17. doi:10.1038/nrc2353
37. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin avß3 for angiogenesis. Science (1994) 264:569-71. doi:10.1126/science.7512751
38. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by avß3-targeted magnetic resonance imaging. Nat Med (1998) 4:623-6. doi:10.1038/nm0598-623
39. Beck V, Herold H, Benge A, Luber B, Hutzler P, Tschesche H, et al. ADAM15 decreases integrin avß3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion. Int J Biochem Cell Biol (2005) 37:590-603. doi:10.1016/j.biocel.2004.08.005
40. Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS. MicroPET and autoradiographic imaging of breast cancer av-integrin expression using 18F-and 64Cu-labeled RGD peptide. Bioconjug Chem (2004) 15:41-9. doi:10.1021/bc0300403
41. Brooks PC, Strömblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin avß3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest (1995) 96:1815-22. doi:10.1172/JCI118227
42. Meerovitch K, Bergeron F, Leblond L, Grouix B, Poirier C, Bubenik M, et al. A novel RGD antagonist that targets both avß3 and a5ß1 induces apoptosis of angiogenic endothelial cells on type I collagen. Vascul Pharmacol (2003) 40:77-89. doi:10.1016/S1537-1891(02)00339-7
43. Ji S, Xu J, Zhang B, Yao W, Xu W, Wu W, et al. RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy. Cancer Biol Ther (2012) 13:206-15. doi:10.4161/cbt.13.4.18692
44. Dubey PK, Singodia D, Verma RK, Vyas SP. RGD modified albumin nanospheres for tumour vasculature targeting. J Pharm Pharmacol (2011) 63:33-40. doi:10.1111/j.2042-7158.2010.01180.x
45. Temming K, Meyer DL, Zabinski R, Dijkers EC, Poelstra K, Molema G, et al. Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels. Bioconjug Chem (2006) 17:1385-94. doi:10.1021/bc060087z
46. Wenk E, Wandrey AJ, Merkle HP, Meinel L. Silk fibroin spheres as a platform for controlled drug delivery. J Control Release (2008) 132:26-34. doi:10.1016/j.jconrel.2008.08.005
47. Wohlrab S, Müller S, Schmidt A, Neubauer S, Kessler H, Leal-Egaña A, et al. Cell adhesion and proliferation on RGD-modified recombinant spider silk proteins. Biomaterials (2012) 33:6650-9. doi:10.1016/j.biomaterials.2012.05.069
48. Arnold M, Cavalcanti-Adam EA, Glass R, Blümmel J, Eck W, Kantlehner M, et al. Activation of integrin function by nanopatterned adhesive interfaces. Chemphyschem (2004) 5:383-8. doi:10.1002/cphc.200301014
49. Arosio D, Manzoni L, Araldi EM, Scolastico C. Cyclic RGD functionalized gold nanoparticles for tumor targeting. Bioconjug Chem (2011) 22:664-72. doi:10.1021/bc100448r
50. Yang X, Hong H, Grailer JJ, Rowland IJ, Javadi A, Hurley SA, et al. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials (2011) 32:4151-60. doi:10.1016/j.biomaterials.2011.02.006
51. Gormley AJ, Malugin A, Ray A, Robinson R, Ghandehari H. Biological evaluation of RGDfK-gold nanorod conjugates for prostate cancer treatment. J Drug Target (2011) 19:915-24. doi:10.3109/1061186X.2011.623701
52. Akhavan O, Ghaderi E, Emamy H. Nontoxic concentrations of PEGylated graphene nanoribbons for selective cancer cell imaging and photothermal therapy. J Mater Chem (2012) 22:20626-33. doi:10.1039/c2jm34330d
53. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin a5ß1 with the central cell-binding domain of fibronectin. Am J Pathol (2000) 156:1345-62. doi:10.1016/S0002-9440(10)65005-5
54. Kim S, Harris M, Varner JA. Regulation of integrin avß3-mediated endothelial cell migration and angiogenesis by integrin a5ß1 and protein kinase A. J Biol Chem (2000) 275:33920-8. doi:10.1074/jbc.M003668200
55. Jayne DG, Heath RM, Dewhurst O, Scott N, Guillou PJ. Extracellular matrix proteins and chemoradiotherapy: a5ß1 integrin as a predictive marker in rectal cancer. Eur J Surg Oncol (2002) 28:30-6. doi:10.1053/ejso.2001.1182
56. Jia Y, Zeng ZZ, Markwart SM, Rockwood KF, Ignatoski KM, Ethier SP, et al. Integrin fibronectin receptors in matrix metalloproteinase-1-dependent invasion by breast cancer and mammary epithelial cells. Cancer Res (2004) 64:8674-81. doi:10.1158/0008-5472.CAN-04-0069
57. Chen J, De S, Brainard J, Byzova TV. Metastatic properties of prostate cancer cells are controlled by VEGF. Cell Commun Adhes (2004) 11:1-11. doi:10.1080/15419060490471739
58. Kim S, Bakre M, Yin H, Varner JA. Inhibition of endothelial cell survival and angiogenesis by protein kinase A. J Clin Invest (2002) 110:933-41. doi:10.1172/JCI0214268
59. van der Flier A, Badu-Nkansah K, Whittaker CA, Crowley D, Bronson RT, Lacy-Hulbert A, et al. Endothelial a5 and av integrins cooperate in remodeling of the vasculature during development. Development (2010) 137:2439-49. doi:10.1242/dev.049551
60. Garg A, Tisdale AW, Haidari E, Kokkoli E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int J Pharm (2009) 366:201-10. doi:10.1016/j.ijpharm.2008.09.016
61. Shroff K, Kokkoli E. PEGylated liposomal doxorubicin targeted to a5ß1-expressing MDA-MB-231 breast cancer cells. Langmuir (2012) 28:4729-36. doi:10.1021/la204466g
62. Pangburn TO, Georgiou K, Bates FS, Kokkoli E. Targeted polymersome delivery of siRNA induces cell death of breast cancer cells dependent upon Orai3 protein expression. Langmuir (2012) 28:12816-30. doi:10.1021/la300874z
63. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, et al. The integrin avß6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell (1999) 96:319-28. doi:10.1016/S0092-8674(00)80545-0
64. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem (2000) 275:21785-8. doi:10.1074/jbc.R000003200
65. Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep (2010) 11:97-105. doi:10.1038/embor.2009.276
66. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, et al. Transcriptional activation of integrin ß6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest (2005) 115:339-47. doi:10.1172/JCI23183
67. Ahmed N, Pansino F, Baker M, Rice G, Quinn M. Association between avß6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. J Cell Biochem (2002) 84:675-86. doi:10.1002/jcb.10080
68. Elayadi AN, Samli KN, Prudkin L, Liu YH, Bian A, Xie XJ, et al. A peptide selected by biopanning identifies the integrin avß6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res (2007) 67:5889-95. doi:10.1158/0008-5472.CAN-07-0245
69. Prudkin L, Liu DD, Ozburn NC, Sun MH, Behrens C, Tang X, et al. Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol (2009) 22:668-78. doi:10.1038/modpathol.2009.19
70. Hausner SH, DiCara D, Marik J, Marshall JF, Sutcliffe JL. Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin avß6 expression with positron emission tomography. Cancer Res (2007) 67:7833-40. doi:10.1158/0008-5472.CAN-07-1026
71. Kawashima A, Tsugawa S, Boku A, Kobayashi M, Minamoto T, Nakanishi I, et al. Expression of av integrin family in gastric carcinomas: increased avß6 is associated with lymph node metastasis. Pathol Res Pract (2003) 199:57-64. doi:10.1078/0344-0338-00355
72. Goodman SL, Hölzemann G, Sulyok GAG, Kessler H. Nanomolar small molecule inhibitors for avß6, avß5, and avß3 integrins. J Med Chem (2002) 45:1045-51. doi:10.1021/jm0102598
73. Bochen A, Marelli UK, Otto E, Pallarola D, Mas-Moruno C, Di Leva FS, et al. Biselectivity of isoDGR peptides for fibronectin binding integrin subtypes a5ß1 and avß6: conformational control through flanking amino acids. J Med Chem (2013) 56:1509-19. doi:10.1021/jm301221x
74. Hsiao JR, Chang Y, Chen YL, Hsieh SH, Hsu KF, Wang CF, et al. Cyclic avß6-targeting peptide selected from biopanning with clinical potential for head and neck squamous cell carcinoma. Head Neck (2010) 32:160-72. doi:10.1002/hed.21166
75. Oyama T, Sykes KF, Samli KN, Minna JD, Johnston SA, Brown KC. Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents. Cancer Lett (2003) 202:219-30. doi:10.1016/j.canlet.2003.08.011
76. Guan H, McGuire MJ, Li S, Brown KC. Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of avß6-positive cancers. Bioconjug Chem (2008) 19:1813-21. doi:10.1021/bc800154f
77. Li S, Gray BP, McGuire MJ, Brown KC. Synthesis and biological evaluation of a peptide-paclitaxel conjugate which targets the integrin avß6. Bioorg Med Chem (2011) 19:5480-9. doi:10.1016/j.bmc.2011.07.046
78. Gray BP, Li SZ, Brown KC. From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker. Bioconjug Chem (2013) 24:85-96. doi:10.1021/bc300498d
79. Guthi JS, Yang SG, Huang G, Li SZ, Khemtong C, Kessinger CW, et al. MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. Mol Pharm (2007) 7:32-40. doi:10.1021/mp9001393
80. DiCara D, Rapisarda C, Sutcliffe JL, Violette SM, Weinreb PH, Hart IR, et al. Structure-function analysis of Arg-Gly-Asp helix motifs in avß6 integrin ligands. J Biol Chem (2007) 282:9657-65. doi:10.1074/jbc.M610461200
81. Logan D, Abughazaleh R, Blakemore W, Curry S, Jackson T, King A, et al. Structure of a major immunogenic site on foot-and-mouth disease virus. Nature (1993) 362:566-8. doi:10.1038/362566a0
82. Hausner SH, Marik J, Gagnon MK, Sutcliffe JL. In vivo positron emission tomography (PET) imaging with an avß6 specific peptide radiolabeled using 18F-"click" chemistry: evaluation and comparison with the corresponding 4-[18F]fluorobenzoyl-and 2-[18F]fluoropropionyl-peptides. J Med Chem (2008) 51:5901-4. doi:10.1021/jm800608s
83. Hausner SH, Abbey CK, Bold RJ, Gagnon MK, Marik J, Marshall JF, et al. Targeted in vivo imaging of integrin avß6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res (2009) 69:5843-50. doi:10.1158/0008-5472.CAN-08-4410
84. Hausner SH, Carpenter RD, Bauer N, Sutcliffe JL. Evaluation of an integrin avß6-specific peptide labeled with [18F]fluorine by copper-free, strain-promoted click chemistry. Nucl Med Biol (2013) 40:233-9. doi:10.1016/j.nucmedbio.2012.10.007
85. Saha A, Ellison D, Thomas GJ, Vallath S, Mather SJ, Hart IR, et al. High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin avß6. J Pathol (2010) 222:52-63. doi:10.1002/path.2745
86. Coughlan L, Vallath S, Saha A, Flak M, McNeish IA, Vassaux G, et al. In vivo retargeting of adenovirus type 5 to avß6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J Virol (2009) 83:6416-28. doi:10.1128/JVI.00445-09
87. Kimura RH, Teed R, Hackel BJ, Pysz MA, Chuang CZ, Sathirachinda A, et al. Pharmacokinetically stabilized cystine knot peptides that bind avß6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin Cancer Res (2012) 18:839-49. doi:10.1158/1078-0432.CCR-11-1116
88. Hackel BJ, Kimura RH, Miao Z, Liu H, Sathirachinda A, Cheng Z, et al. 18F-fluorobenzoate-labeled cystine knot peptides for PET imaging of integrin avß6. J Nucl Med (2013) 54(7):1101-5. doi:10.2967/jnumed.112.110759
89. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell (2009) 15:167-70. doi:10.1016/j.ccr.2009.02.007
90. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett (2012) 320:130-7. doi:10.1016/j.canlet.2012.03.008
91. Heckmann D, Meyer A, Marinelli L, Zahn G, Stragies R, Kessler H. Probing integrin selectivity: rational design of highly active and selective ligands for the a5ß1 and avß3 integrin receptor. Angew Chem Int Ed Engl (2007) 46:3571-4. doi:10.1002/anie.200700008
92. Heckmann D, Meyer A, Laufer B, Zahn G, Stragies R, Kessler H. Rational design of highly active and selective ligands for the a5ß1 integrin receptor. Chembiochem (2008) 9:1397-407. doi:10.1002/cbic.200890032
93. Rechenmacher F, Neubauer S, Polleux J, Mas-Moruno C, De Simone M, Cavalcanti-Adam EA, et al. Functionalizing avß3-or a5ß1-selective integrin antagonists for surface coating: a method to discriminate integrin subtypes in vitro. Angew Chem Int Ed Engl (2013) 52:1572-5. doi:10.1002/anie.201206370
94. Rechenmacher F, Neubauer S, Mas-Moruno C, Dorfner PM, Polleux J, Guasch J, et al. A Molecular toolkit for the functionalization of titanium-based biomaterials that selectively control integrin-mediated cell adhesion. Chem Eur J (2013) 19(28):9218-23. doi:10.1002/chem.201301478
95. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A (2008) 105:9343-8. doi:10.1073/pnas.0803728105
96. Xiao Y, Hong H, Javadi A, Engle JW, Xu W, Yang Y, et al. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials (2012) 33:3071-82. doi:10.1016/j.biomaterials.2011.12.030
97. Ding H, Yong KT, Roy I, Hu R, Wu F, Zhao L, et al. Bioconjugated PLGA-4-arm-PEG branched polymeric nanoparticles as novel tumor targeting carriers. Nanotechnology (2011) 22:165101. doi:10.1088/0957-4484/22/16/165101
98. Eldar-Boock A, Miller K, Sanchis J, Lupu R, Vicent MJ, Satchi-Fainaro R. Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials (2011) 32:3862-74. doi:10.1016/j.biomaterials.2011.01.073
99. Danhier F, Vroman B, Lecouturier N, Crokart N, Pourcelle V, Freichels H, et al. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J Control Release (2009) 140:166-73. doi:10.1016/j.jconrel.2009.08.011
100. Zhan C, Gu B, Xie C, Li J, Liu Y, Lu W. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release (2010) 143:136-42. doi:10.1016/j.jconrel.2009.12.020
101. Liu P, Qin L, Wang Q, Sun Y, Zhu M, Shen M, et al. cRGD-functionalized mPEG-PLGA-PLL nanoparticles for imaging and therapy of breast cancer. Biomaterials (2012) 33:6739-47. doi:10.1016/j.biomaterials.2012.06.008
102. Yin P, Wang Y, Qiu Y, Hou L, Liu X, Qin J, et al. Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity. Int J Nanomedicine (2012) 7:3961-9. doi:10.2147/IJN.S32063
103. Borgman MP, Ray A, Kolhatkar RB, Sausville EA, Burger AM, Ghandehari H. Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy. Pharm Res (2009) 26:1407-18. doi:10.1007/s11095-009-9851-0
104. Borgman MP, Aras O, Geyser-Stoops S, Sausville EA, Ghandehari H. Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery. Mol Pharm (2009) 6:1836-47. doi:10.1021/mp900134c
105. Greish K, Ray A, Bauer H, Larson N, Malugin A, Pike D, et al. Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy. J Control Release (2011) 151:263-70. doi:10.1016/j.jconrel.2010.12.015
106. Ray A, Larson N, Pike DB, Grüner M, Naik S, Bauer H, et al. Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates. Mol Pharm (2011) 8:1090-9. doi:10.1021/mp100402n
107. Zhang P, Hu L, Yin Q, Feng L, Li Y. Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential blood-brain barrier penetration and glioma targeting therapy. Mol Pharm (2012) 9:1590-8. doi:10.1021/mp200600t
108. Xu Q, Liu Y, Su S, Li W, Chen C, Wu Y. Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles. Biomaterials (2012) 33:1627-39. doi:10.1016/j.biomaterials.2011.11.012
109. Winter PM, Schmieder AH, Caruthers SD, Keene JL, Zhang H, Wickline SA, et al. Minute dosages of avß3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J (2008) 22:2758-67. doi:10.1096/fj.07-103929
110. Kim Y, Pourgholami MH, Morris DL, Stenzel MH. An optimized RGD-decorated micellar drug delivery system for albendazole for the treatment of ovarian cancer: from RAFT polymer synthesis to cellular uptake. Macromol Biosci (2011) 11:219-33. doi:10.1002/mabi.201000293
111. Oba M, Fukushima S, Kanayama N, Aoyagi K, Nishiyama N, Koyama H, et al. Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing avß3 and avß5 integrins. Bioconjug Chem (2007) 18:1415-1123. doi:10.1021/bc0700133
112. Oba M, Aoyagi K, Miyata K, Matsumoto Y, Itaka K, Nishiyama N, et al. Polyplex micelles with cyclic RGD peptide ligands and disulfide cross-links directing to the enhanced transfection via controlled intracellular trafficking. Mol Pharm (2008) 5:1080-92. doi:10.1021/mp800070s
113. Oba M, Vachutinsky Y, Miyata K, Kano MR, Ikeda S, Nishiyama N, et al. Antiangiogenic gene therapy of solid tumor by systemic injection of polyplex micelles loading plasmid DNA encoding soluble flt-1. Mol Pharm (2010) 7:501-9. doi:10.1021/mp9002317
114. Vachutinsky Y, Oba M, Miyata K, Hiki S, Kano MR, Nishiyama N, et al. Antiangiogenic gene therapy of experimental pancreatic tumor by sFlt-1 plasmid DNA carried by RGD-modified crosslinked polyplex micelles. J Control Release (2011) 149:51-7. doi:10.1016/j.jconrel.2010.02.002
115. Nie Y, Schaffert D, Rödl W, Ogris M, Wagner E, Günther M. Dual-targeted polyplexes: one step towards a synthetic virus for cancer gene therapy. J Control Release (2011) 152:127-34. doi:10.1016/j.jconrel.2011.02.028
116. Merkel OM, Germershaus O, Wada CK, Tarcha PJ, Merdan T, Kissel T. Integrin avß3 targeted gene delivery using RGD peptidomimetic conjugates with copolymers of PEGylated poly(ethylene imine). Bioconjug Chem (2009) 20:1270-80. doi:10.1021/bc9001695
117. Zhan C, Meng Q, Li Q, Feng L, Zhu J, Lu W. Cyclic RGD-polyethylene glycol-polyethylenimine for intracranial glioblastoma-targeted gene delivery. Chem Asian J (2012) 7:91-6. doi:10.1002/asia.201100570
118. Ng QK, Sutton MK, Soonsawad P, Xing L, Cheng H, Segura T. Engineering clustered ligand binding into nonviral vectors: avß3 targeting as an example. Mol Ther (2009) 17:828-36. doi:10.1038/mt.2009.11
119. Martin I, Dohmen C, Mas-Moruno C, Troiber C, Kos P, Schaffert D, et al. Solid-phase-assisted synthesis of targeting peptide-PEG-oligo(ethane amino)amides for receptor-mediated gene delivery. Org Biomol Chem (2012) 10:3258-68. doi:10.1039/c2ob06907e
120. Yonenaga N, Kenjo E, Asai T, Tsuruta A, Shimizu K, Dewa T, et al. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment. J Control Release (2012) 160:177-81. doi:10.1016/j.jconrel.2011.10.004
121. Xiong XB, Uludag H, Lavasanifar A. Virus-mimetic polymeric micelles for targeted siRNA delivery. Biomaterials (2010) 31:5886-93. doi:10.1016/j.biomaterials.2010.03.075